Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Allied Market Research

Pneumonia Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027

A11230
Pages: NA
Jul 2021 | 55 Views
 
Author(s) : Onkar Sumant
Tables: NA
Charts: NA
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pneumonia Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027

Request Now !

Infection that causes inflammation in air sacs in one or both lungs may be caused due to pneumonia. With pneumonia, the air sacs may fill with fluid or pus. The infection can be life-threatening to anyone, but are particularly lethal to infants, children and people over 65. Symptoms include a cough with phlegm or pus, fever, chills and difficulty breathing. Antibiotics can treat many forms of pneumonia. Some forms of pneumonia can be prevented by vaccines. There are various types of Pneumonia which include Viral Pneumonia, Chlamydial Pneumonias, Hospital-Acquired Pneumonia (Nosocomial Pneumonia) and Ventilator-Associated Pneumonia, Aspiration Pneumonitis and Pneumonia, Pneumocystis jiroveci Pneumonia (PJP), and Community-Acquired Pneumonia (CAP). According to the type of the disease the medications are to be given.

Pneumonia-Therapeutics

Market scope and structure analysis:

Report Metric

Details

  Market size available for years

  2020–2027

  Base year considered

  2019

  Forecast period

  2021–2027

  Forecast units

  Value (USD)

  Segments covered

  Medication, End User and Region

  Regions covered

North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM) and The Middle East and Africa

  Companies covered

Major players analyzed include GlaxoSmithKline plc., Pfizer, Inc., Novartis AG, Bayer AG, Abbott, Merck & Co., Inc., Allergan, and Lupin Pharmaceuticals, Inc.

 

COVID-19 scenario analysis:

The Pharmaceutical and biotech companies shook hands with governments around the globe are working to address the COVID-19 outbreak, which supports in the development of vaccines to planning for medicines supply chain challenges. Furthermore, about 115 vaccine candidates and 155 molecules are in the R&D pipeline. The commonly used drugs which include Hydroxychloroquine have witnessed dramatic increase in demand for the management of COVID-19. The higher demand for these drugs has presented higher opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. The increase in demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The major factor affecting the market includes the rise in the incidences of pneumonia would boost the market in the coming years. The increase in community-acquired pneumonia is expected to propel the industry in the forecast period. Furthermore, the increase in product launches after FDA approval would help the industry gain maximum revenue. The surge in the clinical trials for the R&D of the pneumonia therapeutics is projected to help the industry grow in the next few years.

New product advancements to flourish the market

In August 2019, the U.S. Food and Drug Administration approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease.

In October 2019, Melinta Therapeutics, Inc., a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.

Surge in mergers and acquisitions to boost the market

In August 2017, Melinta Therapeutics had merged with Cempra. The agreement brings together two of the biotechs plugging away, with mixed success, at late-phase development of anti-infective drugs. New Haven, Connecticut-based Melinta will emerge from the merger as the dominant partner.

Furthermore, its name will stay above the door and its shareholders will control 52% of the combined company. But, unlike other reverse mergers involving biotechs that have truly hit the skids, Cempra, for better or worse, brings more than just its NASDAQ listing and cash reserves to the union.

Key segments covered:

Segments

Sub-segments

  Medications

  • Drugs
  • Cephalosporins
  • Tetracyclines
  • Quinolones
  • Aminopenicillins
  • Carbapenems
  • Others
  • Vaccines

  End User

  • Hospitals
  • Clinics
  • Others

 

Key benefits of the report:

  • This study presents the analytical depiction of the global Pneumonia Therapeutics industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Pneumonia Therapeutics market share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Pneumonia Therapeutics market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Pneumonia Therapeutics market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Pneumonia Therapeutics Market research report:

  • Who are the leading market players active in the Pneumonia Therapeutics market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in tasking further strategic steps?
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 
PURCHASE OPTIONS

Start reading ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

 
Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research

Access from any device, anywhere

Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

REQUEST TOC/SAMPLE

OR

Purchase Full Report of
Pneumonia Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $5,192
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $8,096
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers